Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

Last updated: October 13, 2025
Sponsor: Johns Hopkins University
Overall Status: Active - Recruiting

Phase

2

Condition

Vascular Diseases

Scleroderma

Treatment

Placebo

Sildenafil

Clinical Study ID

NCT04797286
IRB00265164
  • Ages > 18
  • All Genders

Study Summary

This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Previous documentation of mean pulmonary artery pressure between 21 and 24 mm Hgwith a pulmonary capillary wedge pressure (or left ventricular end-diastolicpressure) ≤ 15 mm Hg within six months before study entry.

  • Diagnosis of SSc according to 2013 American College of Rheumatology/ European LeagueAgainst Rheumatism (ACR/EULAR) classification criteria.

  • Pulmonary function tests with forced expiratory volume in one second/forced vitalcapacity (FEV1/FVC) >50% AND either a) total lung capacity (TLC) or forced vitalcapacity (FVC) > 70% predicted or b) TLC or FVC between 60% and 70% predicted withno more than mild interstitial lung disease on computerized tomography scan of thechest on studies obtained within 6 months of enrollment.

  • Ventilation perfusion scan or computed tomography with intravenous contrast (CTangiogram) without evidence of chronic thromboembolism at anytime before studyentry.

  • Ability to perform six minute walk testing without significant limitations inmusculoskeletal function or coordination.

  • Informed consent.

Exclusion

Exclusion Criteria:

  • World Health Organization (WHO) Class IV functional status.

  • Systolic blood pressure less than 90 mmHg at screening visit prior to enrollment.

  • Clinically significant untreated sleep apnea.

  • Left-sided valvular disease (more than moderate mitral valve stenosis orinsufficiency or aortic stenosis or insufficiency), pulmonary artery or valvestenosis, or ejection fraction < 45% on most recent echocardiography (within 1year).

  • Use of Pulmonary Arterial Hypertension (PAH) therapy (prostacyclin analogues,endothelin-1 receptor antagonists,phosphodiesterase-5 inhibitors, riociguat,selexipag) within the past 3 months.

  • Hospitalized or acutely ill.

  • Renal failure (creatinine above 2.0) at screening visit.

  • Enrollment in a clinical trial or concurrent use of another investigational drug (non FDA approved) or device therapy within 30 days of screening visit.

  • Age < 18.

  • Currently pregnant.

  • Current use of nitrates.

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
September 20, 2021
Estimated Completion Date:
September 01, 2026

Study Description

Data shows that sildenafil (SIL) is an effective therapy in SSc-PAH. SIL has been safely used in many patients with various vascular and cardiovascular diseases over the past three decades. Randomized controlled trial data for SIL shows improvement in 6MWD, hemodynamics, and even evidence of cardiac remodeling in PAH and SSc-PAH patients. Based upon these data, SIL may be an effective therapy in SSc-MEP. This study will help determine whether sildenafil could be a good treatment for patients with scleroderma that have mildly elevated pulmonary pressures.

Connect with a study center

  • Louisiana State University

    New Orleans, Louisiana 70806
    United States

    Site Not Available

  • Louisiana State University

    New Orleans 4335045, Louisiana 4331987 70806
    United States

    Site Not Available

  • Johns Hopkins

    Baltimore, Maryland 21287
    United States

    Site Not Available

  • Johns Hopkins

    Baltimore 4347778, Maryland 4361885 21287
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.